Drug Profile
Fibroblast growth factor 21 analogue - Novo Nordisk
Alternative Names: FGF-21; FGF-21 NASHLatest Information Update: 16 Feb 2022
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Fibroblast growth factors; Hepatoprotectants
- Mechanism of Action Fibroblast growth factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
Most Recent Events
- 16 Feb 2022 Phase-II clinical trials in Non-alcoholic steatohepatitis in Denmark, before February 2022 (Parenteral) (Novo Nordisk pipeline, February 2022)
- 18 Jan 2022 Pharmacokinetics and pharmacodynamics results from in vivo studies in Non-alcoholic steatohepatitis presented at 72nd Annual Meeting of the American Association for the Study of Liver Diseases
- 18 Nov 2021 Fibroblast growth factor 21 analogue - Novo Nordisk is available for licensing as of 17 Nov 2021. https://www.novonordisk.com/partnering-and-open-innovation/contact-us-about-partnering.html